FDA — authorised 27 November 1985
- Application: NDA019478
- Marketing authorisation holder: BAYER PHARMS
- Local brand name: ADALAT
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 Anti-hypertensive therapy in United States
FDA authorised Anti-hypertensive therapy on 27 November 1985
Marketing authorisations
FDA
- Status: approved
Anti-hypertensive therapy in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Anti-hypertensive therapy approved in United States?
Yes. FDA authorised it on 27 November 1985; FDA has authorised it.
Who is the marketing authorisation holder for Anti-hypertensive therapy in United States?
BAYER PHARMS holds the US marketing authorisation.